New York, May 22, 2026, 19:07 EDT
- Cardiff Oncology plans an investor webcast on June 3, following its updated Phase 2 CRDF-004 data release at ASCO on June 2.
- CRDF ended the session at $1.78, off 0.6%. After the bell, quotes were seen near $1.79.
- Investors are asking if the data backs Cardiff’s push to a Phase 3 registrational trial.
Cardiff Oncology (CRDF) was flat on Friday. The biotech said it plans an investor webcast in June to go over new mid-stage data for onvansertib, the company’s main candidate in first-line RAS-mutated metastatic colorectal cancer.
Cardiff’s key moment comes with its ASCO presentation on June 2 and the webcast the following morning, which will be the next look at the CRDF-004 trial. That trial is now front and center for the company. Shares ended at $1.78, off 0.6%. After hours, the stock was hovering around $1.79.
Cardiff said Thursday it plans to present new Phase 2 data in a rapid oral at the American Society of Clinical Oncology annual meeting, and will bring management on for a webcast June 3 at 8:30 a.m. ET. The trial is looking at onvansertib added to standard chemo and bevacizumab in people with metastatic colorectal cancer—disease spread outside the colon or rectum.
Onvansertib is a PLK1 inhibitor, targeting polo-like kinase 1, an enzyme that plays a part in cancer cell division. The CRDF-004 study is a Phase 2 trial, testing dose, safety, and early signals of benefit ahead of a possible Phase 3. Cardiff’s latest 10-Q shows the trial enrolled 110 patients and is measuring objective response rate — the portion of patients whose tumors shrink by a set amount — and progression-free survival, or time to disease getting worse.
No. 3510, “Onvansertib plus standard-of-care chemotherapy plus bevacizumab in first-line RAS-mutated metastatic colorectal cancer: Interim results from the phase 2 randomized CRDF-004 trial,” will be presented at ASCO on June 2 in Chicago. Cardiff Oncology, Inc.
Prior data are what’s behind the stock’s current catalyst. Cardiff said in January that the 30 mg onvansertib plus FOLFIRI/bevacizumab arm posted a confirmed objective response rate of 72.2%. That compares to 43.2% across the combined standard-of-care arms. Cardiff also put out a progression-free survival hazard ratio of 0.37 against those same arms. A hazard ratio below 1 means lower risk for disease getting worse or death in the treatment group.
Cardiff CEO Mani Mohindru said this month the company now has agreement on main design details for the planned Phase 3 trial, following an End-of-Phase 2 meeting with the FDA. For that study, Cardiff went with the 30 mg dose of onvansertib paired with FOLFIRI and bevacizumab.
Cardiff’s balance sheet is tight. As of March 31, the company said it had $46.1 million in cash, cash equivalents and short-term investments. In its quarterly filing, Cardiff said that cash should fund operations into the first quarter of 2027, but not for a full year after these financial statements came out. Management flagged “substantial doubt” about Cardiff’s ability to keep operating as a going concern. Cardiff Oncology, Inc.
Analyst coverage still leans positive, but there isn’t much new to drive things here. Piper Sandler’s Overweight rating with a $6 target from Feb. 25 is the last update in Benzinga’s database. The consensus target for the seven analysts listed is $9.93.
Competition is out there. FDA listings show Amgen’s Lumakras with Vectibix and Bristol Myers/Mirati’s Krazati plus cetuximab both have green lights for KRAS G12C-mutated metastatic colorectal cancer patients who’ve already had treatment, which is a smaller group than Cardiff’s first-line RAS-mutated push. Cardiff won’t have head-to-head data, but the market will stack its signal’s strength, safety, and maturity against existing targeted drugs.
But the June update is a risk either way. Small biotech stocks like Cardiff can swing on small trial changes. Cardiff still needs to prove its earlier mid-stage data sticks in a bigger, registrational trial. If the response looks weaker, disease-control benefit is shorter, safety comes up, or financing worries build—even with timelines intact—the stock could take a hit.
U.S. equity markets won’t open Monday, May 25, for Memorial Day, Nasdaq’s 2026 holiday calendar shows. Cardiff traders now only have a handful of full sessions before ASCO, which makes the question clear: buy before Cardiff’s June 2 data or sit tight until results drop.
